Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy

Stefano Fais · Giulietta Venturi · Bob Gatenby

Published online: 7 November 2014 © The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract Much effort is currently devoted to developing patient-specific cancer therapy based on molecular characterization of tumors. In particular, this approach seeks to identify driver mutations that can be blocked through small molecular inhibitors. However, this approach is limited by extensive intratumoral genetic heterogeneity, and, not surprisingly, even dramatic initial responses are typically of limited duration as resistant tumor clones rapidly emerge and proliferate. We propose an alternative approach based on observations that while tumor evolution produces genetic divergence, it is also associated with striking phenotypic convergence that loosely correspond to the well-known cancer “hallmarks”. These convergent properties can be described as driver phenotypes and may be more consistently and robustly expressed than genetic targets. To this purpose, it is necessary to identify strategies that are critical for cancer progression and metastases, and it is likely that these driver phenotypes will be closely related to cancer “hallmarks”. It appears that an antiacidic approach, by targetting a driver phenotype in tumors, may be thought as a future strategy against tumors in either preventing the occurrence of cancer or treating tumor patients with multiple aims, including the improvement of efficacy of existing therapies, possibly reducing their systemic side effects, and controlling tumor growth, progression, and metastasis. This may be achieved with existing molecules such as proton pump inhibitors (PPIs) and buffers such as sodium bicarbonate, citrate, or TRIS.

Keywords Acidity · Cancer · Microenvironment · pH gradient · Proton export mechanisms · Proton pump inhibitors

Abbreviations

GLUT-1 Glucose transporter-1
CA Carbonic anhydrase
NHE Sodium hydrogen exchanger
pHe Extracellular pH
pHi Cytoplasmic pH
V-ATPase Vacuolar-type ATPase
MCT Monocarboxylate transporter
PPIs Proton pump inhibitors
CHC α-cyano-4-hydroxycinnamate
DIDS 4,4′-di-isothiocyanostilbene-2,2′-disulfonate
DBDS 4,4′-dibenzamidostilbene-2,2′-disulfonate
AO Acridine orange
DDSs Drug delivery systems

1 Introduction

1.1 The physical microenvironment in tumors

All phases of the development and growth of tumors and their responses to therapies are critically influenced by the tumor physical microenvironment. Here, physical microenvironment refers to key substrate and metabolites (oxygen, glucose, and pH) as well as growth and regulatory factors which are typically transported to and from tissue primarily by the
vascular system. The structure and function of the vasculature, therefore, strongly influence the physical microenvironment, and in cancers, there is marked spatial and temporal variation in blood flow [1]. In part, this is due to failure of the blood vessel formation (angiogenesis), and in part, it reflects chaotic blood flow due to failure of maturation in intratumoral blood vessels. In turn, this creates regional and temporal variations in environmental conditions with complex gradients of glucose, oxygen, H\(^+\), and other substrates and metabolites (Fig. 1). Tumor cell density is typically dependent on environmental conditions so that regions of almost total cell death (necrosis) are often visualized in tumors (Fig. 2).

Thus, tumor cells must adapt to a wide range of environments within tumors, and this is undoubtedly an important factor in the observed intratumoral molecular heterogeneity. However, cancer cells also play an active role in determining their environment, an evolutionary strategy termed “niche engineering” [2] (beaver dams being an obvious analogy in nature). Tumor cells often release increased levels of growth factors, which diffuse through the extracellular environment and cause characteristic changes in vascular growth.

Of importance here, cancer cells also commonly alter their environments through the use of anaerobic glucose metabolism [3] (i.e., glucose metabolism to lactic acid) even in the presence of normal oxygen concentrations. This has two specific consequences: (1) increased glucose flux to compensate for decreased efficiency in converting glucose to ATP; and (2) increased production of H\(^+\) ions, which must be extruded into the environment. As a result, cancers often maintain an acidic microenvironment even when vascular density and flow is relatively normal.

It is clear that cancers must be viewed not as a mass of cancer cells but as a complex society containing interacting populations of cancer and normal cells. Multiple studies have now demonstrated that improved understanding of these interactions can improve strategies for cancer prevention and treatment [4–7].

Although many examples of such interactions can be cited, here we focus on the role of extracellular pH as a mechanism by which the environment affects the cancer cells and vice versa. We particularly focus on potential therapeutic strategies that perturb these dynamics and alter tumor development and growth.

In this review, we will emphasize two major issues: (1) the role of tumor associated microenvironmental acidosis in governing tumor growth, invasion, and metastases; and (2) the role of acidosis in altering tumor response to therapy and potential treatment strategies targeting intratumoral acidosis.

1.2 Aerobic glycolysis (the Warburg effect)

It is impossible to discuss the role of pH in cancer without first introducing Warburg’s nearly century old observations [3]. Briefly, mammalian cells can efficiently generate energy from glucose using oxygen to form CO\(_2\) and H\(_2\)O, generating about 36 moles of ATP/mole of glucose. The alternative glycolytic metabolic pathway does not require oxygen so that each glucose molecule is converted to two molecules of lactate generating only two molecules of ATP. In 1867, Pasteur demonstrated that yeast decreases ethanol production following “aeration” of the culture media. This observation led to an enduring paradigm that in the absence of pathology, cells optimize the efficiency of ATP production within environmental constraints. Thus, high efficiency oxidative phosphorylation (up to 36 ATP/glucose) is generally assumed to be the default source of ATP under physiological conditions, whereas the Embden-Meyerhoff fermentative (glycolytic) pathway, glycolysis (two ATP/glucose), is the “emergency backup” to be used only when oxygen is deficient. Warburg first noted that transformed cells are an exception to these principles. That is, cancer cells frequently exhibit high rates of lactate production even in the presence of oxygen (aerobic glycolysis).

The Warburg effect was originally ascribed to a failure of oxidative metabolism [8], but mitochondrial dysfunction is observed in only a small subset of cancers [9, 10]. Alternatively, it has been suggested that the Warburg effect, through its production of lactate, provides necessary carbon substrate for biosynthesis of macromolecules [11, 12]. However, experimental observations have demonstrated that only a very small percentage of lactate molecules produced by aerobic glycolysis (<7 %) is retained in the cancer cell and glutamine serves as the major carbon source [13]. Furthermore, aerobic glycolysis is commonly observed in normal, proliferating, and non-proliferating cells [9, 14–16]. Thus, although Warburg first observed of aerobic glycolysis over 70 years ago, its biological basis in cancer and normal cells remains unclear [15].
For decades, the Warburg effect, although well recognized, was largely relegated to a laboratory curiosity. However, interest in aerobic glycolysis has significantly expanded with the advent of widespread application of FdG-PET imaging. It is now clear that the vast majority of clinical cancers exhibit increased glucose uptake and, as a consequence of increased aerobic glycolysis, are significantly more acidic than normal tissue [15]. Many investigations of the molecular mechanism of the Warburg effect have provided insights into how aerobic glycolysis emerges in cancer cell. Less clear is the question of why it develops. That is, in the conventional model of carcinogenesis as an evolutionary process, it is initially difficult to understand the Darwinian dynamics leading to consistent selection for aerobic glycolysis which is less energetically efficient than oxidative phosphorylation and produces large amounts of acid. The latter requires energy to be exported from the cell and results in a potentially toxic acidic microenvironment since most mammalian cells cannot survive prolonged exposure to an extracellular pH lower than 7.2.

We and others [4, 16–18] have addressed this evolutionary conundrum with the fundamental assumption that due to the Darwinian dynamics that govern somatic evolution, every common phenotype observed in cancer populations must confer an adaptive advantage. With insights provided by mathematical models, we have proposed that the Warburg effect increases the fitness of cancer cells through a number of mechanisms. One such mechanism involves potential advantages of acid production. In general, we propose that aerobic glycolysis represents an evolutionary strategy described as “niche engineering” in which a population generates environmental properties that decrease the fitness of its competitors. That is, the cancer cells having evolved adaptive strategies to evade acid-mediated toxicity, create an acidic environment that reduces the fitness of other normal and tumor populations (Fig. 3). Furthermore, we have previously demonstrated that regional acidosis can promote invasion through breakdown of extracellular matrix and can inhibit immune response to tumor antigens.

2 Acidosis in carcinogenesis and cancer prevention

Here, we focus largely on Warburg physiology and its resulting acidosis in clinical cancers and their therapy. Less well-investigated are the evolutionary dynamics that select for aerobic glycolysis during carcinogenesis. Transition from normal tissue to invasive cancer is a multi-step process in which increasingly malignant cellular populations emerge over time generally coincident with accumulating genomic mutations. This is often described as “somatic evolution” because it appears formally analogous to Darwinian evolution in nature [19–22]. While this conceptual model is well accepted, the interactions with phenotypic properties and environmental selection forces that determine individual fitness remain ill-defined [18]. Both observational and computational analyses of intraductal carcinogenesis have found evidence for both hypoxia and acidosis. This is largely due to regional environmental variations in intraductal tumor caused by separation from blood vessels which remain in the ductal stroma separated from the tumor cells by the intact basement membrane [3, 23–25]. This is supported by expression of the hypoxia-induced glucose transporter, GLUT-1, and carbonic anhydrase isofrom 9, CA-IX, adjacent to necrotic zones in DCIS as well as the upregulation of GLUT-1 and sodium hydrogen exchanger (NHE-1, a marker for extracellular acidosis) in regions of microinvasion [26]. Notably, adaptation to hypoxia and acidosis has been shown to be critical for the transition from in situ to invasive tumor in human cervical cancer [4].

Computer simulations [25] have demonstrated that changes in microenvironmental pH can slow the rate of evolution in in situ cancers. This was supported by a recent study showing that sodium bicarbonate added to drinking water in TRAMP mice dramatically delayed the transition from in situ to invasive prostate cancer [5].
3 Role of tumor acidity in drug resistance

Microenvironmental acidity plays an important role in the response of malignant tumors to a wide variety of drugs and is likely a leading cause of chemotherapeutic failure in cancer treatment. A key factor in this resistance is the “reversed pH” gradient. That is, cancer cells are characterized by both an acidic extracellular pH (pHe) and a normal or alkaline cytoplasmic pH (pHi) [27, 28]. The alkaline pHi appears to confer resistance to both the hostile acidic milieu and drug cytotoxicity [29–33]. A number of studies have demonstrated that resistance to cisplatin and doxorubicin is associated with an elevation of pHi in multiple tumor cell lines (human epidermoid cancer, human prostate cancer, human ovarian cancer, and myeloma, a series of human lung and breast cancer cell lines) [33–37]. Similarly, cancer cell lines that are evolved to become drug resistant have a more alkaline pHi and a more acidic pH in subcellular organs when compared to the wild-type drug sensitive cells (HL60, K562, CEM, and MCF7) [38]. Many human spontaneous tumors have similar reversed gradients suggesting a clinical relevance for these studies [39]. While there are many potential mechanisms of resistance, it is clear that reversed pHe/pHi gradient interferes with the passage of drugs across the lipid bilayer of cells. Many anticancer drugs (such as doxorubicin and mitoxantrone) are weak bases which are neutralized and inactivated by protonation in the acidic microenvironment surrounding the cells or sequestered in intracellular acidic vesicles or endosomes [40–42]. An additional pH-dependent mechanism of drug resistance, recently described for cisplatin, includes both extracellular sequestration and exosomes mediated elimination of the drug from melanoma cells [43]. Interestingly, other studies have shown that an acidic pH increases the tumor cell exosomes release as well [44].

3.1 Strategies of tumor cells to survive in an acidic environment

As noted above, cancer cells may use acid as a form of niche engineering in which they actively build an environment that is favorable for their own growth and survival but toxic to competitors and potential predators (such as the immune system). This appears to represent an evolutionary strategy termed “spite” in which an individual evolves a strategy that decreases its own fitness but with the benefit (in this case an acidic environment) that reduces the fitness of other normal and tumor populations and, thus, promotes growth and invasion. A key component of this putative evolutionary sequence is acquisition of adaptive strategies to evade acid-mediated toxicity [45]. These strategies include a series of proton export mechanisms, which are found both in the lipid bilayer of the external cell membrane and in intracellular compartmental membranes, including vacuolar type ATPase (V-ATPase) and the proton transporters NHE-1, monocarboxylate...
transporters (MCTs), CAs (mainly CA-IX), adenosine triphosphate synthase, Na\(^+\)/HCO\(_3\)(–) co-transporter, and the Cl\(^–\)/HCO\(_3\)(–) exchanger. These proton pumps are known to be overexpressed and/or overactivated in cancer cells when compared with their non-transformed counterparts. The availability of several inhibitors specific for these proton extrusion mechanisms has allowed investigation of their role in the maintenance of the reversed proton gradient and consequently in the acquisition of the malignant phenotype.

V-ATPase is an enzyme composed of multiple subunits, ubiquitously present in the membranes of vacuolar systems of animal cells. It is critical in vacuole acidification, thus, playing a crucial role in receptor-mediated endocytosis, intracellular trafficking of late endosomes, the transport of lysosomal enzymes from the Golgi apparatus to lysosomes, and the creation of the microenvironment necessary for proper protein trafficking of late endosomes, the transport of lysosomal enzymes from the Golgi apparatus to lysosomes, and the creation of the microenvironment necessary for proper protein transport, exchange, and secretion [46, 47]. V-ATPases can also be expressed in the plasma membrane of cancer cells [48–59] probably due to their enhanced exocytotic events and membrane-recycling mechanisms. Messenger RNAs and/or protein expression levels of different V-ATPase subunits have been shown to be increased in several cancer tissues and cell lines (human hepatocellular carcinoma, breast tumors and melanomas, esophageal squamous cancer cells, oral squamous cell carcinoma, human pancreatic carcinoma, and non-small cell lung cancer) compared with normal tissues [48, 51, 55, 60–64]. Moreover, the intensity of V-ATPase expression has been reported to associate to the pathological type and grade, both in non-small cell lung cancer and in pancreatic carcinoma [48, 55]. V-ATPase overexpression and its localization to the plasma membrane have been associated with the malignant phenotype in terms of invasiveness and metastatic potential and drug resistance [35, 48–50, 61, 62]. Recently, the increased expression of subunit of V-ATPases on the membrane of human melanoma cells deriving from metastatic lesions has been clearly shown [65] suggesting a role in cancer progression and in the metastatic cascade. These data may provide a new marker of tumor malignancy.

The membrane-bound NHEs represent another class of proteins that can extrude protons in exchange for a cation to maintain intracellular electroneutrality. They are present at the surface of most cells where they have a central role in regulating cellular volume and pH homeostasis. NHE isoform 1 (NHE-1) is the most common isoform of the NHEs family, and it is ubiquitous in all mammalian cells. In normal cells, NHE-1 activity is allosterically increased with decreasing pH\(_i\), resulting in rapid activation and subsequent elevation of pH\(_i\) as a consequence of increased proton extrusion [66]. An aberrantly elevated NHE-1 activity has been correlated in tumors with pH\(_i\)/pHi gradient reversal and in turn, associated with tumor origin, local growth, and further progression of the metastatic process [67, 68]. Molecular mechanisms underlying this tumor associated NHE-1 constitutive activation are only recently becoming evident. NHE-1 regulation occurs through the phosphorylation of key amino acids in the cytosolic domain as well as by its interaction with other intracellular proteins and lipids. Ultimately, NHE-1 regulators alter transport activity by altering its affinity for intracellular H\(^+\) such that it is more active at a more alkaline pH\(_i\) [69]. In breast cancer cells, NHE-1 is highly expressed in invadopodia, invasive protrusions capable of proteolytic degradation of the extracellular matrix, where they play an essential role in creating the acidic extracellular microenvironment that facilitates proteases activity [70, 71]. As yet, large clinical studies examining NHE-1 expression in human tumors are lacking. However, recently NHE genes expression was found to be strongly upregulated in several lung cancer histotypes [60]. Interestingly, the expression change patterns have been reported to be highly complementary between NHE genes and the V-ATPase genes in different cancer types, suggesting that the NHE antiporters may play a complementary role to that of the V-ATPases [60].

Monocarboxylate transporters (MCTs) are proton symporters that transport monocarboxylates such as l-lactate, pyruvate, and the ketone bodies across the plasma membrane. There are four isoforms, MCTs 1–4, which are known to perform this function in mammals, each with distinct substrate and inhibitor affinities. MCTs play essential metabolic roles in most tissues, with their distinct properties, expression profile, and subcellular localization matching the particular metabolic needs of a tissue. They also play a key role in maintaining the pH homeostasis [72]. MCT1, MCT2, and MCT4 genes have been shown to be upregulated in several cancer histotypes (breast, colon, lung, ovary) with a considerable variation in the MCT isoforms expressed in different tumors [73, 74]. MCT1, MCT4, and their chaperone CD147 are overexpressed in the plasma membrane of glioblastomas compared with diffuse astrocytomas and non-neoplastic brain [75]. MCT1 and MCT4 both have elevated activity in human melanoma cells in response to low extracellular pH [76]. MCT1 has been reported to be upregulated in neuroblastoma cells, and elevated MCT1 mRNA levels have been detected in fresh neuroblastoma biopsy samples, with a positive correlation between expression level and risk of fatal outcome [77]. Xu et al. [60] recently reported MCT genes to be upregulated in breast, colon, liver, and two lung (adenocarcinoma, squamous cell carcinoma) cancers, but not in prostate cancer. Interestingly, lactate released as a waste product of glycolytic energy production in hypoxic tumor microenvironment has been demonstrated to constitute a prominent substrate that fuels the oxidative metabolism of tumor cells in oxygenated regions, and MCT1 has been shown to be involved in lactate uptake by a human cervix squamous carcinoma cell line that preferentially utilized lactate for oxidative metabolism [78].

Carbonic anhydrases (CA) and HCO\(_3\)– transporters have also been found to play a role in neutralizing the protons in cancer cells. The membrane-bound CAs catalyze the otherwise
slow reaction from $\text{CO}_2 + \text{H}_2\text{O}\rightarrow \text{H}_2\text{CO}_3$, which dissociates into $\text{HCO}_3^-$ (bicarbonate) and $\text{H}^+$ in an acidic extracellular environment. The $\text{HCO}_3^-$ is then transported across the membrane through an HCO$_3^-$ transporter into the intracellular environment, where it reacts with a $\text{H}^+$ to form $\text{CO}_2$ and $\text{H}_2\text{O}$; the $\text{CO}_2$ is freely membrane-permeable and diffuses out of the cell, forming a cycle for removing excess $\text{H}^+$ [79, 80]. CA isoform 9 is known to be inducible by hypoxia [81] and, unlike most other CA isoforms, is associated with many tumors [82, 83]. Very few normal tissues, with the exception of stomach [84], express significant levels of CA9 so that positive staining for CA9 is considered an established marker of tumor hypoxia and a clinical indicator of aggressive cancers (for example, breast and bone) with poor prognosis [85–87]. In addition to CA9, CA12 and CA14 genes have been recently reported to show upregulation in breast, colon, liver, and two lung (adenocarcinoma, squamous cell carcinoma) cancers (but not in prostate cancer), with two HCO$_3^-$ transporters, NBC2 (SLC4A5) and NBC3 (SLC4A7), also being upregulated in colon, liver, and two lung cancers types analyzed [60].

3.2 Summary

Normal function of mammalian cells requires robust mechanism to regulate their pH [88], by sensing changes and then rapidly responding by moving acids and/or bases across the plasma membrane. Cytosolic pH is extraordinarily important, affecting the ionization state of all intracellular weak acids and weak bases, a large number of cellular macromolecules including all proteins. Small perturbation in intracellular pH may potentially affect a wide array of biological processes. In the pathological process of cancer development, the acidification of tumor microenvironment represents an evolutionary advantage both for invasion and proliferation and for response to many chemotherapeutic treatments. Thus, upregulation of proton pumps is necessary to generate the slightly alkaline pH and markedly acidic pHe, which are essential for cancer biology and response to treatment. As our understanding of these mechanisms increases so do opportunities for new cancer specific therapeutic targets.

4 Proton exchangers as a therapeutic target

The reversal of pH gradient in cancer cells is increasingly considered as a hallmark of virtually all cancers [89–91]. And, thus, proton extrusion mechanisms represent appealing targets for new and less toxic anticancer treatment strategies [92]. Indeed, several studies have shown that targeting membrane proton pumps can cause cancer cell death, inhibit proliferation, reduce invasiveness and metastasis formation, and restore sensitivity of drug-resistant cancer cells to chemotherapeutics.

**V-ATPases inhibitors** Many studies have shown a key role of V-ATPases in drug resistance, cancer cells invasiveness, and in their capacity to migrate. Thus, there is much interest in the potential role of anti V-ATPases inhibitors as anticancer drugs, both as monotherapy and in combination with different chemotherapeutics [93, 94]. A growing number of V-ATPases inhibitors are reported to be effective against several cancer histotypes. The first V-ATPase inhibitors to be discovered were bafilomycin and concanamycin [95]. However, these drugs and their subsequent derivatives have proven too toxic to be used as antitumor drugs. More recently, other V-ATPases inhibitors belonging to the benzolactone enamide class, such as salicylilahalamide, lobatamides, and oximides, have been described. With the achievement of total syntheses of salicylilahalamide, lobatamide, and related compounds, the elaboration of congeners with specificity for particular enzyme isoforms may provide drug candidates that are less toxic [96, 97]. Limited supplies have so far precluded extensive *in vivo* testing of the benzolactone enamides.

An alternative approach for inhibiting the V-ATPase is silencing the expression of selected subunits using small interfering RNAs (siRNA) [54, 57, 98–100]. Isoform specific siRNAs employed to selectively target mRNAs isoforms preferably expressed on cancer cells [54] might result in a less toxic cancer therapy.

**Proton pump inhibitors** Among several anti-V-ATPases approaches, the most promising results have been obtained with PPIs, a class of potent antiacidic drugs (Table 1), designed for treatment of peptic diseases. These drugs have been used by billions of people worldwide in the last decades, without significant side effects, even at high doses (as in patients with Zollinger-Hellison syndrome). Interestingly, the absence of toxicity for this class of drugs is largely due to their dependence on an acidic pH for activation [101]. Thus, unlike the vast majority of the drugs including anticancer drugs, PPIs require an acidic environment for activation. As lipophilic and weakly basic prodrugs, they easily penetrate cell membranes and concentrate in acidic compartments, where they are unstable and are converted into sulfonamide forms which are the active inhibitors [102] (Fig. 4).

Based on these properties, PPIs have been extensively investigated for their potential to reduce tumor acidity and overcome the acid related chemoresistance. Furthermore, PPIs could have direct tumor cell toxicity by depriving them of a key mechanism for maintaining pHi/pHe gradient. A number of studies have now shown that PPIs can be useful in modulating tumor acidification and restoring chemotherapeutic sensitivity in drug-resistant cancer cells both *in vitro* and *in vivo* [58, 103–106]. These preclinical data have been supported by clinical studies in companion animals with spontaneous tumors [107] and in patients with osteosarcoma [103].
In addition, specific cytotoxic effects of PPIs on tumor cells have been reported [52, 65, 106, 108–112]. As expected, the PPI-induced cytotoxicity is strongly enhanced in low pH culture conditions [65]. PPIs’ activity has been investigated in several human tumor histotypes, such as melanoma [58, 65, 109], B cell lymphomas [108], pancreatic cancer [106], gastric carcinoma [104, 105, 110, 111], Ewing sarcoma [52], osteosarcoma [103, 112], rhabdomyosarcoma, and chondrosarcoma [112]. PPIs have also been shown to overcome the acidity-induced tumor immune escape mechanisms [113–115]. Finally, based on meta-analysis of observational studies and multicenter prospective cohort study, administration of PPIs in patients with Barrett’s esophagus significantly reduces the risk of esophageal adenocarcinoma and/or high grade dysplasia [116, 117].

**NHE-1 inhibitors** Inhibition of NHE-1 represents an additional potential target in anticancer therapy. Indeed, NHE-1 inhibitors have demonstrated efficacy in malignant glioma [118], hepatocellular carcinoma cells [119], and breast cancer cells [120]. Moreover, NHE-1 inhibition has been found to augment paclitaxel [91], imatinib [121], doxorubicin [122] and cisplatin [123] sensitivity in cancer cells. Amiloride was the first NHE inhibitor developed and has been shown to have a direct antitumoral and antimetastatic effect, *in vitro* and *in vivo* [124, 125]. Amiloride is a potassium-sparing diuretic, first approved in 1967 for management of hypertension and congestive heart failure. In the subsequent 40 years, it has been shown to be well tolerated and safe in humans. Cariporide is more recent but well studied specific and powerful NHE-1 inhibitor, for which an antitumor effect has been reported [68]. It has been shown to be useful in overcoming drug resistance and inhibiting the metastatic process [126]. Cariporide has undergone clinical trials in a cardiological setting and for ischemic reperfusion injury and is generally well tolerated. However, some side effects mainly related to drug accumulation and cerebrovascular complications have been reported. Importantly, the potency of cariporide and some other NHE-1 inhibitors are related to the ionization state of the guanidine residues. Thus, the acidic extracellular pH of tumors would be expected to augment the efficacy of these drugs, a potential advantage in terms of dose dependent side effects.

**Carbonic anhydrases inhibitors** CA9 is an attractive target for anticancer therapy, because it is selectively expressed by tumor cells and shows highly restricted expression in normal tissue. Pharmacologic interference of CA9 catalytic activity using monoclonal antibodies or CA9 specific small molecule inhibitors has been shown recently to impair primary tumor growth and metastasis. Among several classes of small molecules known to effectively inhibit CAs, compounds based on sulfonamide/sulfamates and coumarins, particularly chemotypes of these compounds selective for extracellular CAs such as CA9 [127, 128], have demonstrated a promise as potential anticancer agents. Treatment of hypoxic, metastatic 4 T1 mouse breast tumors with a fluorescent sulfonamide CA9 inhibitor resulted in a significant inhibition of tumor growth.

### Table 1: Comparison of pharmacokinetics of proton pump inhibitors

| Proton pump inhibitors | Chemical structure | Bioavailability(%) | t<sub>max</sub> (h) | t<sub>1/2</sub> (h) | Protein binding (%) |
|------------------------|--------------------|-------------------|-------------------|-------------------|-------------------|
| Omeprazole (20)        | ![Omeprazole structure](image) | 35–60             | 2                 | 0.5–1             | 95                |
| Lansoprazole (30)      | ![Lansoprazole structure](image) | >80               | 1.7               | 1.5               | 97–99             |
| Rabeprazole (20)       | ![Rabeprazole structure](image) | 52                | 3.5               | 1                 | 95–98             |
| Pantoprazole (20)      | ![Pantoprazole structure](image) | 77                | 2.5               | 1                 | 98                |

* t<sub>max</sub>: time to maximum serum concentration
* t<sub>1/2</sub>: elimination half-life
Furthermore, ureido sulfonamide [127] and glycosyl coumarin [128] inhibitors of CA9 produced significant inhibition of primary tumor growth in human and mouse models of orthotopic breast cancer. Treatment of HT-29 xenografts with the high affinity inhibitor of CA9 indanesulfonamide reduced tumor growth, and further regression was observed when the inhibitor was used in combination with radiotherapy [130]. Recent data suggest that sulfonamide and coumarin inhibitors of CA9 activity are also efficacious in reducing metastatic burden in preclinical models. For example, ureido sulfonamides significantly decrease lung metastases from breast cancer [127, 129], and similar results were achieved using glycosyl coumarins [128, 129].

MCTs inhibitors A number of inhibitors of MCTs have been described such as α-cyano-4-hydroxycinnamate (CHC) and its analogues, stilbene disulfonates including 4,4’-di-isothiocyanostilbene-2,2’-disulfonate (DIDS) and 4,4’-dibenzamidostilbene-2,2’-disulfonate (DBDS), phloretin, and bioflavanoids such as quercetin [72, 131]. However, none of these is specific for MCTs. CHC is a potent inhibitor of the mitochondrial pyruvate
transporter [72], while DIDS and DBDS inhibit the chloro
dioxide/bicarbonate exchanger AE1 much more power-
fully than MCT1 [72, 131]. MCTs inhibition with CHC has re
culting in a decrease of tumor cell pH in in vitro melanoma and neuroblastoma models [76, 77]. Interest-
ingly, CHC activity increased when cultivating cells in an acidic medium [76]. Inhibiting MCT1 with CHC or siRNA induced a switch from lactate fueled respiration to glycolysis in a human cervix squamous carcinoma cell line that preferentially utilized lactate for oxidative metabo-

in plasma membranes [72], while DIDS and DBDS inhibit the chloro
dioxide/bicarbonate exchanger AE1 much more power-
fully than MCT1 [72, 131]. MCTs inhibition with CHC has re
culting in a decrease of tumor cell pH in in vitro melanoma and neuroblastoma models [76, 77]. Interest-
ingly, CHC activity increased when cultivating cells in an acidic medium [76]. Inhibiting MCT1 with CHC or siRNA induced a switch from lactate fueled respiration to glycolysis in a human cervix squamous carcinoma cell line that preferentially utilized lactate for oxidative metabo-

in plasma membranes [72], while DIDS and DBDS inhibit the chloro
dioxide/bicarbonate exchanger AE1 much more power-
fully than MCT1 [72, 131]. MCTs inhibition with CHC has re
culting in a decrease of tumor cell pH in in vitro melanoma and neuroblastoma models [76, 77]. Interest-
ingly, CHC activity increased when cultivating cells in an acidic medium [76]. Inhibiting MCT1 with CHC or siRNA induced a switch from lactate fueled respiration to glycolysis in a human cervix squamous carcinoma cell line that preferentially utilized lactate for oxidative metabo-

in plasma membranes [72], while DIDS and DBDS inhibit the chloro
dioxide/bicarbonate exchanger AE1 much more power-
fully than MCT1 [72, 131]. MCTs inhibition with CHC has re
culting in a decrease of tumor cell pH in in vitro melanoma and neuroblastoma models [76, 77]. Interest-
ingly, CHC activity increased when cultivating cells in an acidic medium [76]. Inhibiting MCT1 with CHC or siRNA induced a switch from lactate fueled respiration to glycolysis in a human cervix squamous carcinoma cell line that preferentially utilized lactate for oxidative metabo-

In addition to proton extrusion mechanisms, cancer microen-
venvironmental can be viewed as a potential target for anticancer therapy and a number of potential strategies are available.

Acridine orange AO is known to accumulate densely in in-
tracellular vesicles, especially lysosomes, in an acidity depen-
dent manner. AO shows marked and prolonged accumulation in cancer cells, since these contain many strongly acidic lysosomes [133] and is, therefore, useful for visualizing tumor cells during surgery through a fluorescent microscope. Fur-
thermore, it is used for photodynamic therapy, as it has a strong cytocidal effect on tumor cells following excitation through blue light or low dose radiation [134]. Kusazaki et al. [134–136] have developed an innovative approach using minimally invasive surgery combined with photo and radiodynamic therapy with AO for treatment of musculoskeletal sarcomas. They report improved postoperative limb function when compared with conventional surgery with wide tumor resection. Clinical pilot studies have yielded excellent results, with low local recurrence rates, good prognosis, and excellent limb function [136–139].

pH-Sensitive nanosystems for drug delivery in cancer ther-
apy have been reviewed recently [140]. A variety of nanomaterials responding to physical, chemical, or biological stimuli have been synthesized and investigated as drug delivery systems (DDSs). Among these, pH-sensitive systems have been most widely used for drug delivery in cancer therapy. According to their constituents, nanomaterials can be classi-
ified as organic, inorganic, or hybrid. One approach optimizes intratumoral drug release using nanomaterials with “ioniz-
able” chemical groups, such as amines, phosphoric acids, and carboxylic acids that undergo pH-dependent changes in physical or chemical properties resulting in drug release. An alternative approach uses acid-labile chemical bonds to covalently attach drug molecules directly onto the surfaces of existing nanocarriers or to construct new nanocarriers. These acid-labile chemical bonds are stable at neutral pH but are degraded or hydrolyzed in acidic media. Finally, a novel pH responsive DDSs incorporates carbon dioxide generating pre-
cursors that produce CO2 gas in an acidic environment, leading to disintegration of the carrier and release of drug mole-
cules. This strategy is based on the fact that HCO3− reacts with acid to produce carbonic acid, which easily decomposes to yield carbon dioxide (CO2) gas and water. Common CO2 generating agents include sodium bicarbonate and ammonium bicarbonate, both of which are compatible with normal cellular systems and the tumor microenvironment. Several studies have demonstrated that novel pH-sensitive drug delivery sys-
tems are capable of improving the efficiency of cancer treat-
ment. A number of these have been translated from bench to clinical application and have been approved by the Food and Drug Administration for cancer treatment [140].

5 Tumor acidity as a therapeutic target

Increased acid production is a consequence of increased an-
aerobic glucose metabolism in tumors that results from re-
gional hypoxia due to disordered vascular development and the Warburg effect. The evolution of the latter during carcino-
genesis is likely favored by the benefits of increased acid production which promotes invasion and proliferation of the cancer cells at the expense of their competitors and blunts the immune response. This “metabolic dysregulation” is now viewed as a “hallmark” [141] of cancer and confers an additional benefit of promoting tumor cell adaptation to many chemotherapies. However, this reversed acid gradient in can-
cers also provides an inviting target for new therapeutic strat-
egies that are being examined in multiple centers throughout the world.

6 Conclusion

Increased acid production is a consequence of increased an-
aerobic glucose metabolism in tumors that results from re-
gional hypoxia due to disordered vascular development and the Warburg effect. The evolution of the latter during carcino-
genesis is likely favored by the benefits of increased acid production which promotes invasion and proliferation of the cancer cells at the expense of their competitors and blunts the immune response. This “metabolic dysregulation” is now viewed as a “hallmark” [141] of cancer and confers an additional benefit of promoting tumor cell adaptation to many chemotherapies. However, this reversed acid gradient in can-
cers also provides an inviting target for new therapeutic strat-
egies that are being examined in multiple centers throughout the world.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
**References**

1. Hanna, G., Fontanella, A., Palmer, G., Shan, S., Radiollof, D. R., Zhao, Y., Irwin, D., Hamilton, K., Boico, A., Piantadosi, C. A., Bluelsche, G., Dewhirst, M., McMahon, T., & Schroeder, T. (2013). Automated measurement of blood flow velocity and direction and hemoglobin oxygen saturation in the rat lung using intravital microscopy. *American Journal of Physiology. Lung Cellular and Molecular Physiology, 304*(2), L86–L91.

2. Yang, K. R., Mooney, S., Zarif, J. C., Coffey, D. S., Taichman, R. S. & Pienta, K. J. (2014). Niche inheritance: a cooperative pathway to enhance cancer cell fitness through ecosystem engineering. *Journal of Cellular Biochemistry.*

3. Gatenby, R. A., & Gillies, R. J. (2004). Why do cancers have high aerobic glycolysis? *Nature reviews. Cancer.* 4(11), 891–899.

4. Lee, W. Y., Huang, S. C., Hsu, K. F., Tzeng, C. C., & Shen, W. L. (2008). Roles for hypoxia-regulated genes during cervical carcinogenesis: somatic evolution during the hypoxia-glycolysis-acidosis sequence. *Gynecologic Oncology, 108*(2), 377–384.

5. Ibrahim-Hashim, A., Cornnell, H. H., Abrahams, D., Lloyd, M., Bui, M., Gillies, R. J., & Gatenby, R. A. (2012). Systemic buffers inhibit carcinogenesis in TRAMP mice. *The Journal of Urology, 188*(2), 624–631.

6. Estrella, V., Chen, T., Lloyd, M., Wojtkowiak, J., Cornnell, H. H., Ibrahim-Hashim, A., Bailey, K., Balagurunathan, Y., Rothberg, J. M., Sloane, B. F., Johnson, J., Gatenby, R. A., & Gillies, R. J. (2013). Acidity generated by the tumor microenvironment drives local invasion. *Cancer Research, 73*(5), 1524–1535.

7. Robey, I. F., Baggett, B. K., Kirkpatrick, N. D., Roe, D. J., Dosecu, J., Sloane, B. F., Hashim, A. I., Morse, D. L., Raghunandan, N., Gatenby, R. A., & Gillies, R. J. (2009). Bicarbonate increases tumor pH and inhibits spontaneous metastases. *Cancer Research, 69*(6), 2260–2268.

8. Warburg, O. (1956). On the origin of cancer cells. *Science (New York, N.Y.), 123*(3191), 309–314.

9. Zu, X. L., & Guppy, M. (2004). Cancer metabolism: facts, fantasy, and fiction. *Biochemical and Biophysical Research Communications, 313*(3), 459–465.

10. Kroemer, G. (2006). Mitochondria in cancer. *Oncogene, 25*(34), 4630–4632.

11. Hume, D. A., & Weidemann, M. J. (1979). Role and regulation of glucose metabolism in proliferating cells. *Journal of the National Cancer Institute, 62*(1), 3–8.

12. Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science (New York, N.Y.), 324*(5950), 1029–1033.

13. DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007). Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. *Proceedings of the National Academy of Sciences of the United States of America, 104*(49), 19345–19350.

14. Lemons, J. M., Feng, X. J., Bennett, B. D., Legesse-Miller, A., Johnson, E. L., Raitman, I., Pollina, E. A., Rabitz, H. A., Rabinowitz, J. D., & Candelaresi, C., Alpini, G., 2010. Quiescent fibroblasts exhibit high metabolic activity. *PLoS Biology, 8*(10), e1000514.

15. Gillies, R. J., Robey, I., & Gatenby, R. A. (2008). Causes and consequences of increased glucose metabolism of cancers. *Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 49*(Suppl 2), 24S–42S.

16. Gatenby, R. A. (1995). The potential role of transformation-induced metabolic changes in tumor-host interaction. *Cancer Research, 55*(18), 4151–4156.

17. Gillies, R. J., Martinez-Zaguilan, R., Martinez, G. M., Serrano, R., & Perona, R. (1990). Tumorigenic 3T3 cells maintain an alkaline intracellular pH under physiological conditions. *Proceedings of the National Academy of Sciences of the United States of America, 87*(19), 7414–7418.

18. Gatenby, R. A., & Gillies, R. J. (2008). A microenvironmental model of carcinogenesis. *Nature Reviews. Cancer, 8*(1), 56–61.

19. Garcia, S. B., Novelli, M., & Wright, N. A. (2000). The clonal origin and clonal evolution of epithelial tumours. *International Journal of Experimental Pathology, 81*(2), 89–116.

20. Nowell, P. C. (1976). The clonal evolution of tumor cell populations. *Science (New York, N.Y.), 194*(4260), 23–28.

21. Ilyas, M., Straub, J., Tomlinson, I. P., & Bodmer, W. F. (1999). Genetic pathways in colorectal and other cancers. *European Journal of Cancer (Oxford, England: 1990), 35*(3), 335–351.

22. Fearon, E. R., & Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. *Cell, 61*(5), 759–767.

23. Silva, A. S., Gatenby, R. A., Gillies, R. J., & Yunes, J. A. (2010). A quantitative theoretical model for the development of malignancy in ductal carcinoma in situ. *Journal of Theoretical Biology, 262*(4), 601–613.

24. Gatenby, R. A., Smallbone, K., Maini, P. K., Rose, F., Averill, J., Nagle, R. B., Worrall, L., & Gillies, R. J. (2007). Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. *British Journal of Cancer, 97*(5), 646–653.

25. Smallbone, K., Gatenby, R. A., Gillies, R. J., Maini, P. K., & Gavaghan, D. J. (2007). Metabolic changes during carcinogenesis: potential impact on invasiveness. *Journal of Theoretical Biology, 244*(4), 703–713.

26. Wykoff, C. C., Beasley, N., Watson, P. H., Campo, L., Chia, S. K., English, R., Pastorek, J., Sliy, W. S., Ratcliffe, P., & Harris, A. L. (2001). Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. *The American Journal of Pathology, 158*(3), 1011–1019.

27. Huber, V., De Milito, A., Harguiincede, S., Reshkin, S. J., Wahl, M. L., Rauch, C., Chiesi, A., Pouyssegur, J., Gatenby, R. A., Rivoltini, L., & Fais, S. (2010). Proton dynamics in cancer. *Journal of Translational Medicine, 8*, 57.

28. Webb, B. A., Chimenti, M., Jacobson, M. P., & Barber, D. L. (2011). Dysregulated pH: a perfect storm for cancer progression. *Nature Reviews. Cancer, 11*(9), 671–677.

29. Rich, I. N., Worthington-White, D., Garden, O. A., & Musk, P. (2000). Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger. *Blood, 95*(4), 1427–1434.

30. Che, X. F., Zheng, C. L., Akiyama, S., & Tomoda, A. (2011). 2-Aminophenoxyazine-3-one and 2-amino-4,4alpha-dihydro-4alpha,7-dimethyl-3H-phenoxazine-3-one cause cellular apoptosis by reducing intracellular pH associated with inhibition of Na(+)–H(+) exchanger. *American Journal of Pathology, 158*(4), 1256–1261.

31. Nagata, H., Che, X. F., Miyazawa, K., Tomoda, A., Konishi, M., Ubukata, H., & Tabuchi, T. (2011). Rapid decrease of intracellular pH associated with inhibition of Na(+)–H(+) exchanger precedes apoptotic events in the MNK45 and MNK74 gastric cancer cell lines treated with 2-aminophenoxyazine-3-one. *Oncology Reports, 25*(2), 341–346.

32. Di Sario, A., Bendia, E., Omenetti, A., De Minicis, S., Marzioni, M., Kleemann, H. W., Candelaresi, C., Saccomanno, S., Alpini, G., & Benedetti, A. (2007). Selective inhibition of ion transport mechanisms regulating intracellular pH reduces proliferation and induces apoptotic cell death in cholangiocarcinoma cells. *Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 39*(1), 60–69.

33. Roepe, P. D. (1992). Analysis of the steady-state and initial rate of doxorubicin efflux from a series of multidrug-resistant cells expressing different levels of P-glycoprotein. *Biochemistry, 31*(50), 12555–12564.
46. Nishi, T., & Forgac, M. (2002). The vacuolar (H+)-ATPases

44. Parolini, I., Federici, C., Raggi, C., Lugini, L., Palleschi, S., De

42. Ouar, Z., Bens, M., Vignes, C., Paulais, M., Pringel, C., Fleury, J.,

37. Altan, N., Chen, Y., Schindler, M., & Simon, S. M. (1998).

36. Keizer, H. G., & Joenje, H. (1989). Increased cytosolic pH in

370

317

315

313

311

309

307

305

303

301

299

297

295

293

291

289

287

285

283

281

279

277

275

273

271

269

267

265

263

261

259

257

255

253

251

249

247

245

243

241

239

237

235

233

231

229

227

225

223

221

219

217

215

213

211

209

207

205

203

201

199

197

195

193

191

189

187

185

183

181

179

177

175

173

171

169

167

165

163

161

159

157

155

153

151

149

147

145

143

141

139

137

135

133

131

129

127

125

123

121

119

117

115

113

111

109

107

105

103

101

99

97

95

93

91

89

87

85

83

81

79

77

75

73

71

69

67

65

63

61

59

57

55

53

51

49

47

45

43

41

39

37

35

33

31

29

27

25

23

21

19

17

15

13

11

9

7

5

3

1

234

232

230

228

226

224

222

220

218

216

214

212

210

208

206

204

202

200

198

196

194

192

190

188

186

184

182

180

178

176

174

172

170

168

166

164

162

160

158

156

154

152
64. Ohba, T., Numata, M., Yagishita, H., Futagami, F., Tsukiyama, K., Kitagawa, H., Kayahara, M., Nagakawa, T., Miyazaki, I., Yamamoto, M., Iseki, S., & Ohkuma, S. (1996). Expression of 16 kDa proteolipid of vascular-tumor type H(+)-ATPase in human pancreatic cancer. British Journal of Cancer, 73(12), 1511–1517.

65. De Milito, A., Canese, R., Marino, M. L., Borghi, M., Iero, M., Villa, A., Venturelli, G., Lozupone, F., Iessi, E., Logozzi, M., Della Mina, P., Santinami, M., Rodolfi, M., Podo, F., Rivoltini, L., & Fais, S. (2010). pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. International Journal of Cancer, International Du Cancer, 127(1), 207–219.

66. Malo, M. E., & Fliegel, L. (2006). Physiological role and regulation of the Na(+)/H+ exchanger. Canadian Journal of Physiology and Pharmacology, 84(11), 1081–1095.

67. Daniel, C., Bell, C., Burton, C., Harguindeguy, S., Reshkin, S. J., & Rauch, C. (2013). The role of proton dynamics in the development and maintenance of multidrug resistance in cancer. Biochimie et Biophysica Acta, 1832(5), 606–617.

68. Harguindeguy, S., Arranz, J. L., Polo Orozco, J. D., Rauch, C., Fais, S., Cardone, R. A., & Reshkin, S. J. (2013). Carpioride and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs—an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research. Journal of Translational Medicine, 11, 282.

69. Amthi, S. R., & Fliegel, L. (2013). Regulation of the Na(+)/H+ exchanger (NHE1) in breast cancer metastasis. Cancer Research, 73(4), 1259–1264.

70. Magalhaes, M. A., Larson, D. R., Mader, C. C., Bravo-Cordero, J. J., Gil-Henn, H., Oser, M., Chen, X., Koleske, A. J., & Condeelis, J. (2011). Cortactin phosphorylation regulates cell invasion through a pH-dependent pathway. The Journal of Cell Biology, 195(5), 903–920.

71. Bourguignon, L. Y., Singleton, P. A., Diedrich, F., Stern, R., & Gilad, E. (2004). CD44 interaction with Na+/H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin E. (2004). CD44 interaction with Na+/H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin E. Biophysical Journal, 87(5), 1264–1273.

72. Halestrap, A. P. (2012). The monocarboxylate transporter family. IUBMB Life, 64(1), 1–9.

73. Ganapathy, V., Thangaraju, M., & Prasad, P. D. (2009). Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacology & Therapeutics, 121(1), 29–40.

74. Pinheiro, C., Reis, R. M., Ricardo, S., Longatto-Filho, A., Schmitt, F., & Baltazar, F. (2010). Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. Journal of Biomedicine & Biotechnology, 2010, 427694.

75. Miranda-Goncalves, V., Honavar, M., Pinheiro, C., Martinho, O., Pires, M. M., Pinheiro, C., Cordeiro, M., Bebiano, G., Costa, P., Palmeirim, I., Reis, R. M., & Baltazar, F. (2013). Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro-Oncology, 15(2), 172–188.

76. Wahl, M. L., Owen, J. A., Burd, R., Herlands, R. A., Nogami, S. S., Rodeuck, U., Berd, D. B., & Owen, C. S. (2002). Regulation of intracellular pH in human melanoma: potential therapeutic implications. Molecular Cancer Therapeutics, 1(8), 617–628.

77. Fang, J., Quinones, J. Q., Holman, T. L., Morowitiz, M. J., Wang, Q., Zhan, H., Sivo, F., Mari, M. J., & Wahl, M. L. (2006). The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Molecular Pharmacology, 70(6), 2108–2115.

78. Sonveaux, P., Pegragn, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., Kelley, M. J., Gallez, B., Wahl, M. L., Feron, O., & Dewhirst, M. W. (2008). Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. The Journal of Clinical Investigation, 118(12), 3930–3942.

79. Swietach, P., Hulikova, A., Vaughan-Jones, R. D., & Harris, A. L. (2010). New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene, 29(50), 6509–6521.

80. Swietach, P., Vaughan-Jones, R. D., & Harris, A. L. (2007). Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Reviews, 26(2), 299–310.

81. Wykoff, C. C., Beasley, N. J., Watson, P. H., Turner, K. J., Pastorek, J., Sibtain, A., Wilson, G. D., Turley, H., Talks, K. L., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000). Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Research, 60(24), 7075–7083.

82. Pastorek, J., Pastorekova, S., Palmeirim, I., Reis, R. M., & Baltazar, F. (2013). Disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Biochimica et Biophysica Acta, 1804(2), 404–409.

83. De Simone, G., & Supuran, C. T. (2010). Carbonic anhydrase IX: biochemical and crystallographic characterization of a novel antitumor target. Biochimica et Biophysica Acta, 1804(2), 404–409.

84. Pastorekova, S., Parkikila, S., Parkikila, A. K., Opavsky, R., Zelnik, V., Saarnio, J., & Pastorek, J. (1997). Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology, 112(2), 398–408.

85. Chia, S. K., Wykoff, C. C., Watson, P. H., Han, C., Leek, R. D., Pastorek, J., Gatter, K. C., Ratcliffe, P., & Harris, A. L. (2001). Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 19(16), 3660–3668.

86. Giatromanolaki, A., Koukourakis, M. I., Sivridis, E., Pastorek, J., Wykoff, C. C., Gatter, K. C., & Harris, A. L. (2001). Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Research, 61(21), 7992–7998.

87. Generali, D., Fox, S. B., Berruti, A., Brizzi, M. P., Campo, L., Bonardi, S., Wigfield, S. M., Bruzzi, P., Bersiga, A. L., Allegi, V., Milani, M., Agugmini, S., Dogliotti, L., Bottini, A., & Harris, A. L. (2006). Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocrine-Related Cancer, 13(3), 921–930.

88. Roos, A., & Boron, W. F. (1981). Intracellular pH. Physiological Reviews, 61(2), 296–434.

89. Cardone, R. A., Casavola, V., & Reshkin, S. J. (2005). The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nature Reviews. Cancer, 5(10), 786–795.

90. Harguindeguy, S., Orive, G., Luis Pedraz, J., Paradiso, A., & Reshkin, S. J. (2005). The role of pH dynamics and the Na+/H+ antipporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin—one single nature. Biochimica et Biophysica Acta, 1750(1), 1–24.

91. Reshkin, S. J., Cardone, R. A., & Harguindeguy, S. (2013). Na+/H+ exchanger, pH regulation and cancer. Recent Patents on Anti-Cancer Drug Discovery, 8(1), 85–99.

92. Harguindeguy, S., Arranz, J. L., Wahl, M. L., Orive, G., & Reshkin, S. J. (2009). Proton transport inhibitors as potentially selective anticancer drugs. Anticancer Research, 29(6), 2127–2136.

93. Perez-Sayans, M., Somozas-Martin, J. M., Barros-Angueira, F., Rey, J. M., & Garcia-Garcia, A. (2009). V-ATPase inhibitors and implication in cancer treatment. Cancer Treatment Reviews, 35(8), 707–713.
94. Perez-Sayans, M., Somoz-Martin, J. M., Barros-Angueira, F., Diz, P. G., Rey, J. M., & Garcia-Garcia, A. (2010). Multidrug resistance in oral squamous cell carcinoma: the role of vacuolar ATPases. *Cancer Letters*, 295(2), 135–143.

95. Bowman, E. J., Siebers, A., & Altendorf, K. (1988). Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. *Proceedings of the National Academy of Sciences of the United States of America*, 85(21), 7972–7976.

96. Boyd, M. R., Farina, C., Belfiore, P., Gagliardi, S., Kim, J. W., Hayakawa, Y., Beutler, J. A., McKee, T. C., Bowman, B. J., & Bowman, E. J. (2001). Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-ATPases. *The Journal of Pharmacology and Experimental Therapeutics*, 297(1), 114–120.

97. Beutler, J. A., & McKee, T. C. (2003). Novel marine and microbial natural product inhibitors of vacuolar ATPase. *Current Medicinal Chemistry*, 10(9), 787–796.

98. Lu, X., Qin, W., Li, J., Tan, N., Pan, D., Zhang, H., Xie, L., Yao, G., Shu, H., Yao, M., Wan, D., Gu, J., & Yang, S. (2005). The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6P of proton pump. *Cancer Research*, 65(15), 6843–6849.

99. You, H., Jin, J., Shu, H., Yu, B., De Milito, A., Lozupone, F., Deng, Y., Tang, N., Yao, G., Fais, S., Gu, J., & Qin, W. (2009). Small interfering RNA targeting the subunit ATP6P of proton pump V-ATPase overcomes chemoresistance of breast cancer cells. *Cancer Letters*, 289(1), 110–119.

100. Capucci, J., & Forgac, M. (2013). The function of vacuolar ATPase (V-ATPase) a subunit isoforms in invasiveness of MCF10a and multidrug resistance in human gastric adenocarcinoma SGC7901 cells through regulation of phospholRP6 expression in Wnt/beta-catenin signaling. *Oncology Reports*, 30(2), 851–855.

101. Mullin, J. M., Gabello, M., Murray, L. J., Farrell, C. P., Bellone, J., Wolow, K. R., Kearney, K. R., Rudolph, D., & Thornton, J. J. (2013). Effect of proton pump inhibitor pantoprazole in a lymphoma-bearing murine host: Implication in antitumor activation of tumor-associated macrophages. *Immunology Letters*, 134(1), 83–92.

102. Singh, S., Garg, S.K., Singh, P.P., Iyer, P.G. & El-Serag, H.B. (2013). Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut.

103. ferrari, s., perut, f., fagioli, f., brach del prever, a., mezzana, c., parafioriti, a., picci, p., gambarotti, m., avnet, s., baldini, n., & fais, s. (2013). Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients’ bed. *Journal of Translational Medicine*, 11, 268.

104. Chen, M., Zou, X., Luo, H., Cao, J., Zhang, X., Zhang, B., & Liu, W. (2009). Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma SGC7901 cells. *Cell Biology International*, 33(9), 1008–1019.

105. Chen, M., Huang, S. L., Zhang, X. Q., Zhang, B., Zhu, H., Yang, W. W., & Zou, X. P. (2012). Reversal effects of pantoprazole on multidrug resistance of human gastric adenocarcinoma SGC7901 cells through regulation of phosphoLRP6 expression in Wnt/beta-catenin signaling. *Oncology Reports*, 30(2), 851–855.

106. Calcinotto, A., Filippazzi, P., Grioni, M., Iero, M., De Milito, A., Ricupito, A., Cova, A., Canese, R., Jachetti, E., Rossetti, M., Huber, V., Parmiani, G., Generoso, L., Santinami, M., Borghi, M., Fais, S., Bellone, M., & Rivoltini, L. (2012). Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. *Cancer Research*, 72(11), 2746–2756.

107. Vishvakarma, N. K., & Singh, S. M. (2010). Immunopotentiating effect of proton pump inhibitor pantoprazole in a lymphoma-bearing murine host: Implication in antitumor activation of tumor-associated macrophages. *Immunology Letters*, 134(1), 83–92.

108. Harley, W., Floyd, C., Dunn, T., Zhang, X. D., Chen, T. Y., Hegde, M., Palandoken, H., Nantz, M. H., Leon, L., Carraway, K. L., 3rd, Lyeth, B., & Gorin, F. A. (2010). Dual inhibition of sodium-mediated proton and calcium efflux triggers non-apoptotic cell death in malignant gliomas. *Brain Research*, 1363, 159–169.

109. Yang, X., Wang, D., Dong, W., Song, Z., & Dou, K. (2010). Inhibition of Na+−H+ (+) exchanger by S-(N-ethyl-N-isopropyl) amiloride reduces hypoxia-induced hepatocellular carcinoma invasion and motility. *Cancer Letters*, 293(2), 198–204.

110. Chang, W. H., Liu, T. C., Yang, W. K., Lee, C. C., Lin, Y. H., Chen, T. Y., & Chang, J. G. (2011). Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib. *Cancer Research*, 71(2), 383–392.

111. Miraglia, E., Viarisio, D., Riganti, C., Costamagna, C., Ghigo, D., & Bosia, A. (2005). Na+/H+ exchanger activity is increased in

---

**Note:** The above text is a sample representation and may not be a complete or accurate transcription of the original document. It is intended to provide a rough idea of the content. For precise and accurate information, please refer to the original source.
doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. *International Journal of Cancer. International Journal of Cancer*, 115(6), 924–929.

123. Lauritzen, G., Jensen, M. B., Boedtkjer, E., Dybboe, R., Aalkjaer, C., Nylandsted, J., & Pedersen, S. F. (2010). NBCn1 and NHE1 expression and activity in DeltaNerbB2 receptor-expressing MCF-7 breast cancer cells: contributions to pH regulation and chemotherapy resistance. *Experimental Cell Research*, 315(15), 2538–2553.

124. Kellen, J. A., Mirakian, A., & Kolin, A. (1988). Antimetastatic effect of amiloride in an animal tumour model. *Anticancer Research*, 8(6), 1373–1376.

125. Matthews, H., Ranson, M., & Kelso, M. J. (2011). Anti-tumour/ metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty? *International Journal of Cancer. International Journal of Cancer*, 129(9), 2051–2061.

126. Resthok, S. J., Bellizzi, A., Cardone, R. A., Tommasino, M., Casavola, V., & Paradiso, A. (2003). Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, 9(6), 2366–2373.

127. Pacchiano, F., Carta, F., McDonald, P. C., Lou, Y., Vullo, D., Scozzafava, A., Dedhar, S., & Supuran, C. T. (2011). Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimitastatic activity in a model of breast cancer metastasis. *Journal of Medicinal Chemistry*, 54(6), 1896–1902.

128. Toussi, N., Marascia, A., McDonald, P. C., Lou, Y., Scozzafava, A., Dedhar, S., Winum, J. Y., & Supuran, C. T. (2011). Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. *Journal of Medicinal Chemistry*, 54(24), 8271–8277.

129. Lou, Y., McDonald, P. C., Oloumi, A., Chia, S., Ostlund, C., Ahmad, A., Kyle, A., Auf dem Keller, U., Leung, S., Huntsman, D., Clarke, B., Sutherland, B. W., Waterhouse, D., Bally, M., Roskelley, C., Overall, C. M., Minchinton, A., Pacchiano, F., Carta, F., Scozzafava, A., Toussi, N., Winum, J. Y., Supuran, C. T., & Dedhar, S. (2011). Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. *Cancer Research*, 71(9), 3364–3376.

130. Dubois, L., Peeters, S., Lieuves, N. G., Geusens, N., Thiry, A., Wigfield, S., Carta, F., McIntyre, A., Scozzafava, A., Dogne, J. M., Supuran, C. T., Harris, A. L., Masereel, B., & Lambin, P. (2011). Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. *Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology*, 99(3), 424–431.

131. Halestrap, A. P., & Price, N. T. (1999). The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. *The Biochemical Journal*, 343(Pt 2), 281–299.

132. Colen, C. B., Shen, Y., Ghododdusi, F., Yu, P., Francis, T. B., Koch, B. J., Monterey, M. D., Galloway, M. P., Sloan, A. E., & Mathupala, S. P. (2011). Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. *Neoplasia (New York, N.Y.)*, 13(7), 620–632.

133. Matsubara, T., Kusuzaki, K., Matsumine, A., Shintani, K., Satonaka, H., & Uchida, A. (2006). Acridine orange used for photodynamic therapy accumulates in malignant musculoskeletal tumors depending on pH gradient. *Anticancer Research*, 26(1A), 187–193.

134. Hashiguchi, S., Kusuzaki, K., Murata, H., Takeshita, H., Hashiba, M., Nishimura, T., Ashihara, T., & Hirasaki, Y. (2002). Acridine orange excited by low-dose radiation has a strong cytotoxic effect on mouse osteosarcoma. *Oncology*, 62(1), 85–93.

135. Kusuzaki, K., Aomori, K., Sugishita, T., Minami, G., Takeshita, H., Murata, H., Hashiguchi, S., Ashihara, T., & Hirasaki, Y. (2000). Total tumor cell elimination with minimum damage to normal tissues in musculoskeletal sarcomas following photodynamic therapy with acridine orange. *Oncology*, 59(2), 174–180.

136. Kusuzaki, K., Hosogi, S., Ashihara, E., Matsubara, T., Satonaka, H., Nakamura, T., Matsumine, A., Sudo, A., Uchida, A., Murata, H., Baldini, N., Fais, S., & Marunaka, Y. (2012). Translational research of photodynamic therapy with acridine orange which targets cancer acridine. *Current Pharmaceutical Design*, 18(10), 1414–1420.

137. Kusuzaki, K., Murata, H., Matsubara, T., Miyazaki, S., Shintani, K., Seto, M., Matsumine, A., Hoso, H., Sugimoto, T., & Uchida, A. (2005). Clinical outcome of a novel photodynamic therapy technique using acridine orange for synovial sarcomas. *Photochemistry and Photobiology*, 81(3), 705–709.

138. Kusuzaki, K., Murata, H., Matsubara, T., Miyazaki, S., Okamura, A., Seto, M., Matsumine, A., Hoso, H., Sugimoto, T., & Uchida, A. (2005). Clinical trial of photodynamic therapy using acridine orange with/without low dose radiation as new limb salvage modality in musculoskeletal sarcomas. *Anticancer Research*, 25(2B), 1225–1235.

139. Matsubara, T., Kusuzaki, K., Matsumine, A., Murata, H., Nakamura, T., Uchida, A., & Sudo, A. (2010). Clinical outcomes of minimally invasive surgery using acridine orange for musculoskeletal sarcomas around the forearm, compared with conventional limb salvage surgery after wide resection. *Journal of Surgical Oncology*, 102(3), 271–275.

140. Liu, J., Huang, Y., Kumar, A., Tan, A., Jin, S., Mozhai, A., & Liang, X.J. (2013). pH-Sensitive nano-systems for drug delivery in cancer therapy. *Biotechnology Advances*.